242 related articles for article (PubMed ID: 21830212)
1. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation.
Dasgupta S; Soudry E; Mukhopadhyay N; Shao C; Yee J; Lam S; Lam W; Zhang W; Gazdar AF; Fisher PB; Sidransky D
J Cell Physiol; 2012 Jun; 227(6):2451-60. PubMed ID: 21830212
[TBL] [Abstract][Full Text] [Related]
2. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
[TBL] [Abstract][Full Text] [Related]
3. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Hosgood HD; Pao W; Rothman N; Hu W; Pan YH; Kuchinsky K; Jones KD; Xu J; Vermeulen R; Simko J; Lan Q
Respir Med; 2013 Nov; 107(11):1755-62. PubMed ID: 24055406
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Dogan S; Shen R; Ang DC; Johnson ML; D'Angelo SP; Paik PK; Brzostowski EB; Riely GJ; Kris MG; Zakowski MF; Ladanyi M
Clin Cancer Res; 2012 Nov; 18(22):6169-77. PubMed ID: 23014527
[TBL] [Abstract][Full Text] [Related]
5. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.
Ren S; Kuang P; Zheng L; Su C; Li J; Li B; Chen X; Wang Y; KimCurran V; Liu L; Hu Q; Zhang J; Tang L; Zhou C
Cell Biochem Biophys; 2012 Nov; 64(2):155-60. PubMed ID: 22707299
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
7. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG
J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442
[TBL] [Abstract][Full Text] [Related]
8. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ
Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530
[TBL] [Abstract][Full Text] [Related]
9. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
10. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
[TBL] [Abstract][Full Text] [Related]
11. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
12. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
Yamaguchi F; Kugawa S; Tateno H; Kokubu F; Fukuchi K
Lung Cancer; 2012 Dec; 78(3):201-6. PubMed ID: 23026641
[TBL] [Abstract][Full Text] [Related]
13. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
14. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.
Toyooka S; Matsuo K; Shigematsu H; Kosaka T; Tokumo M; Yatabe Y; Ichihara S; Inukai M; Suehisa H; Soh J; Kiura K; Fong KM; Lee H; Wistuba II; Gazdar AF; Mitsudomi T; Date H
Clin Cancer Res; 2007 Oct; 13(19):5763-8. PubMed ID: 17908966
[TBL] [Abstract][Full Text] [Related]
15. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
16. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
[TBL] [Abstract][Full Text] [Related]
17. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas.
Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Mol Med Rep; 2012 Mar; 5(3):599-602. PubMed ID: 22200795
[TBL] [Abstract][Full Text] [Related]
19. Lesions in patients with multifocal adenocarcinoma are more frequently in the right upper lobes.
Kaneda H; Uemura Y; Nakano T; Taniguchi Y; Saito T; Konobu T; Saito Y
Interact Cardiovasc Thorac Surg; 2012 Oct; 15(4):627-32. PubMed ID: 22733594
[TBL] [Abstract][Full Text] [Related]
20. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
